Bayer and its partner Regeneron Pharmaceuticals are collaborating on the global development of the drug for ‘wet’ AMD, central vein occlusion, diabetic macular oeda and myopic choroidal neovascularization.
The drug is claimed to require less-frequent injections once treatment is established – once every two months versus every month, following three loading doses.
All-new Alcon Unity vitreoretinal and cataract systems approved in Australia
Alcon has revealed its “highly anticipated” Unity Vitreoretinal Cataract System and Unity Cataract System have been included on the Australian...
